ArticleAlzheimer's research & therapy2022
A longitudinal study on quality of life along the spectrum of Alzheimer's disease.
Article in Alzheimer's research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- Informant Perspectives on the Quality of Life of Healthy Older People, and People With Dementia Living in the Community and Care Facilities.Australasian journal on ageing · 2026Observational
- Discovering non-linear dynamics of miRNAs in Alzheimer's disease-related cognitive impairment: a cross-species approach with explainable machine learning.Biology direct · 2026Article
- Neuro-psycho MMSig: multimodal mechanism enrichment platform for neuropsychiatric disorders.Frontiers in bioinformatics · 2026Article
- Care pathways for patients with cognitive impairment and chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- Effects of the hospital-community-family trinity cardiac rehabilitation on patients with acute myocardial infarction after percutaneous coronary intervention: A randomized trial.International journal of nursing sciences · 2025Article
- Expression of Neuronal Nicotinic Acetylcholine Receptor and Early Oxidative DNA Damage in Aging Rat Brain-The Effects of Memantine.International journal of molecular sciences · 2025Article
- Quality of Life in People With HIV at the End of Life: Preliminary Results From the Last Gift Observational Cohort Study.Journal of acquired immune deficiency syndromes (1999) · 2025Observational
- Article
- Longitudinal study on health-related quality of life and multimorbidity: from trajectories to outcomes in China.Frontiers in public health · 2025Article
- Multimorbidity patterns and cognitive frailty in adults aged over 50 years: China perspective.Frontiers in public health · 2025Article
- Gait-Based AI Models for Detecting Sarcopenia and Cognitive Decline Using Sensor Fusion.Diagnostics (Basel, Switzerland) · 2024Article
- Review
- Differences in trajectories of quality of life according to type of dementia: 6-year longitudinal findings from the IDEAL programme.BMC medicine · 2024Article
- Potential Impact of Slowing Disease Progression in Early Symptomatic Alzheimer's Disease on Patient Quality of Life, Caregiver Time, and Total Societal Costs: Estimates Based on Findings from GERAS-US Study.Journal of Alzheimer's disease : JAD · 2024Article
- Assessing Quality of Life, Economic Burden, and Independence Across the Alzheimer's Disease Continuum Using Patient-Caregiver Dyad Surveys.Journal of Alzheimer's disease : JAD · 2024Article
- Predictors for quality of life in older adults: network analysis on cognitive and neuropsychiatric symptoms.BMC geriatrics · 2023Article
- Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis.Alzheimer's research & therapy · 2023Article
- Jiedu Yizhi Formula Improves Cognitive Function by Regulating the Gut Dysbiosis and TLR4/NF-κB Signaling Pathway.Neuropsychiatric disease and treatment · 2023Article
- Simulation of long-term lecanemab treatment effect on Alzheimer's disease progression.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundQuality of life (QoL) is an important outcome from the perspective of patients and their caregivers, in both dementia and pre-dementia stages. Yet, little is known about the long-term changes in QoL over time. We aimed to compare the trajectories of QoL between amyloid-positive and amyloid-negative SCD or MCI patients and to evaluate QoL trajectories along the Alzheimer's disease (AD) continuum of cognitively normal to dementia.
methodsWe included longitudinal data of 447 subjective cognitive decline (SCD), 276 mild cognitive impairment (MCI), and 417 AD dementia patients from the Amsterdam Dementia Cohort. We compared QoL trajectories (EQ-5D and visual analog scale (VAS)) between (1) amyloid-positive and amyloid-negative SCD or MCI patients and (2) amyloid-positive SCD, MCI, and dementia patients with linear mixed-effect models. The models were adjusted for age, sex, Charlson Comorbidity Index (CCI), education, and EQ-5D scale (3 or 5 level).
resultsIn SCD, amyloid-positive participants had a higher VAS at baseline but showed a steeper decline over time in EQ-5D and VAS than amyloid-negative participants. Also, in MCI, amyloid-positive patients had higher QoL at baseline but subsequently showed a steeper decline in QoL over time compared to amyloid-negative patients. When we compared amyloid-positive patients along the Alzheimer continuum, we found no difference between SCD, MCI, or dementia in baseline QoL, but QoL decreased at a faster rate in the dementia stage compared with the of SCD and MCI stages.
conclusionsQoL decreased at a faster rate over time in amyloid-positive SCD or MCI patients than amyloid-negative patients. QoL decreases over time along the entire AD continuum of SCD, MCI and dementia, with the strongest decrease in dementia patients. Knowledge of QoL trajectories is essential for the future evaluation of treatments in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.